K-ras and B-raf mutations and anti-EGFr antibody therapy
AssigneeAmgen Inc.
InventorsSalvatore SIENA, Alberto Bardelli
Life of this patent
Estimating the term…
Abstract
The present application relates to K-ras mutations, to polynucleotides encoding mutant K-ras polypeptides, and to methods of identifying K-ras mutations. The present application also relates to B-raf mutations, to polynucleotides encoding mutant B-raf polypeptides, to vectors containing those polynucleotides, and to methods of identifying B-raf mutations. The present application also relates to methods of diagnosing cancer; and methods and kits for predicting the usefulness of anti-EGFr specific binding agents in the treatment of tumors.
Claims12
A method of predicting whether a patient will be nonresponsive to treatment with a specific binding agent to an EGFr polypeptide, comprising determining the presence or absence of a B-raf mutation in a tumor of the patient, wherein the B-raf mutation is in codon 600;
- and wherein if a B-raf mutation is present, the patient is predicted to be nonresponsive to treatment with a specific binding agent to an EGFr polypeptide.
A method of predicting whether a tumor will be nonresponsive to treatment with a specific binding agent to an EGFr polypeptide, comprising determining the presence or absence of a B-raf mutation in a sample of said tumor, wherein the B-raf mutation is in codon 600;
- and wherein the presence of the B-raf mutation indicates that the tumor will be nonresponsive to a specific binding agent to an EGFr polypeptide.
The method of claim 19, wherein the determining the presence or absence of a B-raf mutation in the sample of said tumor comprises detecting a mutant B-raf polypeptide using a specific binding agent to a mutant B-raf polypeptide.
Dependencies are inferred from the claim text.